Asciminib hydrochloride (BioDeep_00000839869)
代谢物信息卡片
化学式: C20H19Cl2F2N5O3 (485.0833)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4.Cl
InChI: /m1./s1
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
同义名列表
1 个代谢物同义名
数据库引用编号
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Matthias Hoch, Felix Huth, Masahiko Sato, Tirtha Sengupta, Michelle Quinlan, Stephanie Dodd, Shruti Kapoor, Florence Hourcade-Potelleret. Pharmacokinetics of asciminib in the presence of CYP3A or P-gp inhibitors, CYP3A inducers, and acid-reducing agents.
Clinical and translational science.
2022 07; 15(7):1698-1712. doi:
10.1111/cts.13285. [PMID: 35616006] - Matthias Hoch, Tirtha Sengupta, Florence Hourcade-Potelleret. Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants.
Clinical and translational science.
2022 06; 15(6):1406-1416. doi:
10.1111/cts.13252. [PMID: 35293131] - Matthias Hoch, Julia Zack, Michelle Quinlan, Felix Huth, Sofia Forte, Stephanie Dodd, Paola Aimone, Florence Hourcade-Potelleret. Pharmacokinetics of Asciminib When Taken With Imatinib or With Food.
Clinical pharmacology in drug development.
2022 02; 11(2):207-219. doi:
10.1002/cpdd.1019. [PMID: 34609077] - Matthias Hoch, Masahiko Sato, Julia Zack, Michelle Quinlan, Tirtha Sengupta, Alex Allepuz, Paola Aimone, Florence Hourcade-Potelleret. Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment.
Journal of clinical pharmacology.
2021 11; 61(11):1454-1465. doi:
10.1002/jcph.1926. [PMID: 34115385] - Helong Zhao, Michelle Mendenhall, Michael W Deininger. Imatinib is not a potent anti-SARS-CoV-2 drug.
Leukemia.
2020 11; 34(11):3085-3087. doi:
10.1038/s41375-020-01045-9. [PMID: 32999432] - Phi Tran, Imad Hanna, Fabian Kurt Eggimann, Joseph Schoepfer, Tapan Ray, Bing Zhu, Lai Wang, Petra Priess, Xianbin Tian, Florence Hourcade-Potelleret, Heidi J Einolf. Disposition of asciminib, a potent BCR-ABL1 tyrosine kinase inhibitor, in healthy male subjects.
Xenobiotica; the fate of foreign compounds in biological systems.
2020 Feb; 50(2):150-169. doi:
10.1080/00498254.2019.1594449. [PMID: 31006307] - Hans D Menssen, Michelle Quinlan, Charisse Kemp, Xianbin Tian. Relative Bioavailability and Food Effect Evaluation for 2 Tablet Formulations of Asciminib in a 2-Arm, Crossover, Randomized, Open-Label Study in Healthy Volunteers.
Clinical pharmacology in drug development.
2019 04; 8(3):385-394. doi:
10.1002/cpdd.602. [PMID: 30059193]
